Mersana Therapeutics (MRSN)

• Market cap: $35.6M
• 1 day: -4.42%
• 5 days: 4.54%
• 1 month: 17.63%
• 3 months: -21.37%
• 6 months: -44.04%
• Year to date: -79.6%
• 1 year: -83.86%
• 5 years: -98.82%
• 10 years: -97.96%
• Sector: Healthcare
• Industry: Biotechnology

About: Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.

Employees: 102

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

250% more call options, than puts

Call options by funds: $14K | Put options by funds: $4K

0.34% less ownership

Funds ownership: 2.82% [Q1] → 2.49% (-0.34%) [Q2]

20% less repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 30

24% less funds holding

Funds holding: 109 [Q1] → 83 (-26) [Q2]

24% less capital invested

Capital invested by funds: $30.3M [Q1] → $22.9M (-$7.34M) [Q2]

67% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 39

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $30
• Avg. target: $33
• High target: $36

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Truist Securities Asthika Goonewardene	$36	Buy Maintained	14 Aug 2025
Guggenheim Michael Schmidt	$30	Buy Maintained	14 Aug 2025